These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


178 related items for PubMed ID: 9158210

  • 1. Use of low-dose low molecular weight heparin in hemodialysis.
    Lai KN, Wang AY, Ho K, Szeto CC, Li M, Wong LK, Yu AW.
    Am J Kidney Dis; 1996 Nov; 28(5):721-6. PubMed ID: 9158210
    [Abstract] [Full Text] [Related]

  • 2. Use of single dose low-molecular-weight heparin in long hemodialysis.
    Lai KN, Ho K, Li M, Szeto CC.
    Int J Artif Organs; 1998 Apr; 21(4):196-200. PubMed ID: 9649059
    [Abstract] [Full Text] [Related]

  • 3. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
    Stefoni S, Cianciolo G, Donati G, Colì L, La Manna G, Raimondi C, Dalmastri V, Orlandi V, D'Addio F.
    Nephron; 2002 Apr; 92(3):589-600. PubMed ID: 12372942
    [Abstract] [Full Text] [Related]

  • 4. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients.
    Janssen MJ, Deegens JK, Kapinga TH, Beukhof JR, Huijgens PC, van Loenen AC, van der Meulen J.
    Kidney Int; 1996 Mar; 49(3):806-13. PubMed ID: 8648924
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
    Sánchez-Canel JJ, Pons-Prades R, Salvetti ML, Seores A, Vázquez M, Pérez-Alba A, Tamarit E, Calvo-Gordo C, Villatoro J.
    Nefrologia; 2012 Mar; 32(5):605-12. PubMed ID: 23013946
    [Abstract] [Full Text] [Related]

  • 6. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J, Haaf B, Dempfle CE, Stehle G, Heene DL.
    Nephrol Dial Transplant; 1995 Mar; 10(2):217-22. PubMed ID: 7753456
    [Abstract] [Full Text] [Related]

  • 7. Dose effect relationship of reviparin in chronic hemodialysis: a crossover study versus nadroparin.
    Reach I, Luong N, Chastang C, Chakroun M, Mirshahi S, Mirshahi MC, Soria J, Desmichels D, Baumelou A.
    Artif Organs; 2001 Jul; 25(7):591-5. PubMed ID: 11493282
    [Abstract] [Full Text] [Related]

  • 8. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
    Pöschel KA, Bucha E, Esslinger HU, Ulbricht K, Nörtersheuser P, Stein G, Nowak G.
    Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
    [Abstract] [Full Text] [Related]

  • 9. Usefulness of thrombelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis.
    Shinoda T, Arakura H, Katakura M, Shirota T, Nakagawa S.
    Artif Organs; 1990 Dec; 14(6):413-5. PubMed ID: 2177970
    [Abstract] [Full Text] [Related]

  • 10. Beneficial effect of low molecular weight heparin on the hemodialysis model in dogs.
    Hamano S, Komatsu H, Ikeda S, Takahashi K, Oguma Y, Sakuragawa N.
    Thromb Res; 1989 Aug 15; 55(4):439-49. PubMed ID: 2554525
    [Abstract] [Full Text] [Related]

  • 11. Low molecular weight heparin in hemodialysis patients with a bleeding tendency.
    Leu JG, Chiang SS, Lin SM, Pai JK, Jiang WW.
    Nephron; 2000 Dec 15; 86(4):499-501. PubMed ID: 11124600
    [Abstract] [Full Text] [Related]

  • 12. [Use of low molecular-weight heparin in hemodialysis patients].
    Schrader J, Rieger J, Müschen H, Stibbe W, Köstering H, Kramer P, Scheler F.
    Klin Wochenschr; 1985 Jan 15; 63(2):49-55. PubMed ID: 3981950
    [Abstract] [Full Text] [Related]

  • 13. Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study.
    Sombolos KI, Fragia TK, Gionanlis LC, Veneti PE, Bamichas GI, Fragidis SK, Georgoulis IE, Natse TA.
    Int J Clin Pharmacol Ther; 2008 Apr 15; 46(4):198-203. PubMed ID: 18397694
    [Abstract] [Full Text] [Related]

  • 14. Effect of switching unfractionated heparin to low-molecular-weight heparin on serum potassium in hemodialysis patients.
    Ezzatzadegan Jahromi S, Mahmoodi MS, Behroozi F, Roozbeh J, Emamghoreishi F.
    Iran J Kidney Dis; 2014 Nov 15; 8(6):475-80. PubMed ID: 25362223
    [Abstract] [Full Text] [Related]

  • 15. Low molecular weight heparin in hemodialysis and hemofiltration patients.
    Schrader J, Valentin R, Tönnis HJ, Hildebrand U, Stibbe W, Armstrong VW, Kandt M, Köstering H, Quellhorst E.
    Kidney Int; 1985 Nov 15; 28(5):823-9. PubMed ID: 3936965
    [Abstract] [Full Text] [Related]

  • 16. Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: a prospective proof-of-concept study.
    Kessler M, Gangemi C, Gutierrez Martones A, Lacombe JL, Krier-Coudert MJ, Galland R, Kielstein JT, Moureau F, Loughraieb N.
    Hemodial Int; 2013 Apr 15; 17(2):282-93. PubMed ID: 22925178
    [Abstract] [Full Text] [Related]

  • 17. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center.
    Lord H, Jean N, Dumont M, Kassis J, Leblanc M.
    Am J Nephrol; 2002 Apr 15; 22(1):58-66. PubMed ID: 11919404
    [Abstract] [Full Text] [Related]

  • 18. Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis.
    Grau E, Sigüenza F, Maduell F, Linares M, Olaso MA, Martinez R, Caridad A.
    Nephron; 1992 Apr 15; 62(1):13-7. PubMed ID: 1331831
    [Abstract] [Full Text] [Related]

  • 19. Practical Value of Anti-Xa Activity in the Evaluation of Extracorporeal Circuit Anticoagulation during Haemodialysis: Results of a Cross-Sectional Single-Centre Study.
    Coene KLM, Dekker MJE, Kerskes MCHM, Hengst M, Schonck MJM, Konings CJAM, Scharnhorst V.
    Nephron; 2017 Apr 15; 137(3):205-211. PubMed ID: 28817831
    [Abstract] [Full Text] [Related]

  • 20. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J, Stehle G, Blauth M, Huck K, Mall K, Heene DL.
    Semin Thromb Hemost; 1997 Apr 15; 23(1):83-90. PubMed ID: 9156415
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.